Pyridazine-Based Pyridine Derivatives for Selective COX-2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing non-steroidal anti-inflammatory drugs (NSAIDs) are non-specific COX inhibitors, leading to gastric ulcerating effects due to COX-1 inhibition, and specific COX-2 inhibitors have side effects like cerebrovascular risk and cardiac toxicity.
Innovation Solution
Development of pyridazine-based pyridine derivatives, or their pharmaceutically acceptable salts, which act as antioxidants, selective COX-2 inhibitors, and antimicrobial agents, thereby addressing the limitations of existing NSAIDs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific COX inhibitors (traditional NSAIDs) are used, then anti-inflammatory effect is achieved, but gastric ulceration occurs due to COX-1 inhibition
Solution Approach 1:
The patent applies local quality by designing a molecule with distinct functional regions: a pyridazine core with specific substituents (R1, R2, R3, R4, R5) that confer selective COX-2 binding affinity while minimizing COX-1 interaction. This spatial differentiation of pharmacological activity within the single molecule resolves the contradiction by localizing the anti-inflammatory effect to COX-2 while preserving COX-1 function in the stomach.
Solution Approach 2:
The patent employs parameter changes by systematically varying substituent parameters (R groups) on the pyridazine core to optimize COX-2 selectivity. By changing chemical parameters such as substituent type, position, and electronic properties, the invention achieves high COX-2 inhibition with reduced COX-1 inhibition, thereby maintaining anti-inflammatory efficacy while reducing gastric ulceration risk.
2Object-affected harmful factors
If specific COX-2 inhibitors are used, then gastric side effects are reduced, but cerebrovascular risk and cardiac toxicity occur
Solution Approach 1:
The patent applies composite materials by creating a hybrid molecular structure that combines the pyridazine scaffold (providing COX-2 selectivity and reduced gastric toxicity) with specific substituent patterns (R1-COOH, R2-CONH2, R3-OH, R4-CF3, R5-SO2NH2) that confer additional beneficial properties including antioxidant activity and reduced cardiovascular risk. This composite structure integrates multiple pharmacological functions to resolve the contradiction between gastric safety and cardiovascular safety.
Solution Approach 2:
The patent implements multi-functionality by designing a single agent that simultaneously provides COX-2 inhibition (anti-inflammatory), antioxidant protection (reducing oxidative stress-related cardiovascular damage), and antimicrobial activity. This universal approach allows the compound to address multiple pathological mechanisms involved in cardiovascular disease while maintaining gastric safety, thereby resolving the contradiction between reduced gastric side effects and cardiovascular risk.
3Reliability
If pyridazine-based pyridine derivatives are developed with multiple activities, then therapeutic efficacy is improved, but molecular complexity increases
Solution Approach 1:
The patent applies merging by consolidating multiple pharmacological activities (COX-2 inhibition, antioxidant, antimicrobial) into a single pyridazine-based pyridine derivative molecule. Rather than using combination therapy with multiple separate drugs, the invention merges these functions into one molecular entity with a core pyridazine structure and strategically placed substituents, thereby achieving enhanced therapeutic efficacy while managing molecular complexity through rational drug design.
Data Source
AI summary
The present disclosure relates to a compound of Formula Iwherein R is selected from the group consisting of —H, —F, —Cl, —Br, —I, —NO2, —CH3, and —C2H5; R1, R2, R3, R4 and R5 are independently selected from the group consisting of —H, —COOH, -, —CONH2, —COOCH3, —COOCH2CH3, —CN, —NO2, —OH, —CF3, —SO2NH2, —F, —Cl, —Br, —I, —OCH3, —CH3, and —COCH3, or a pharmaceutically acceptable salt thereof.